Unique ID issued by UMIN | UMIN000035414 |
---|---|
Receipt number | R000040349 |
Scientific Title | The effect of calcimimetics on complications of chronic kidney disease |
Date of disclosure of the study information | 2018/12/30 |
Last modified on | 2024/02/15 16:24:25 |
The effect of calcimimetics on complications of chronic kidney disease
The effect of calcimimetics on complications of chronic kidney disease
The effect of calcimimetics on complications of chronic kidney disease
The effect of calcimimetics on complications of chronic kidney disease
Japan |
Chronic kidney disease(CKD)
Nephrology |
Others
NO
Examination of the effect of calcimimetics on complications of CKD patients (e.g., bone and mineral metabolism factor, bone mineral density, parathyroid enlargement, left ventricular hypertrophy)
Efficacy
Investigation of the effect of calcimimetics on bone and mineral metabolism factor, bone density, parathyroid enlargement in CKD patients
Effects of calcimimetics on cardiac function and bone metabolism markers in CKD patients
Observational
20 | years-old | <= |
100 | years-old | > |
Male and Female
Chronic kidney disease patients who are visiting our hospital regularly
Patients complicated with serious diseases such as malignancy, heart failure (NYHA III degrees or more), and liver cirrhosis
100
1st name | Michio |
Middle name | |
Last name | Kuwahara |
Saitama Tsukinomori Clinic
Division of Nephrology
339-0012
366-1 Mashinaga, Iwatsuki-ku, Saitama city, Saitama 339-0012, Japan
0487921811
kuwahara@k-naika-cl.jp
1st name | Michio |
Middle name | |
Last name | Kuwahara |
Saitama Tsukinomori Clinic
Division of Nephrology
339-0012
366-1 Masunaga, Iwatsuki-ku, Saitama City, Saitama 339-0012, Japan
0487921811
kuwahara@k-naika-cl.jp
Saitama Tsukinomori Clinic
Saitama Tsukinomori Clinic
Self funding
The Ethics Committee of Saitama Tsukinomori Clinic
366-1 Masunaga, Iwatsuki-ku, Saitama City, Saitama 339-0012, Japan
0487921811
hayama@k-naika-cl.jp
NO
2018 | Year | 12 | Month | 30 | Day |
Unpublished
32
Etelcalcetide was administered to 32 hemodialysis patients with secondary hyperparathyroidism. iPTH, BAP, Osteocalcin, TRACP 5b, and FGF23 decreased significantly, and this decrease persisted.
2024 | Year | 02 | Month | 15 | Day |
Completed
2018 | Year | 12 | Month | 21 | Day |
2018 | Year | 12 | Month | 21 | Day |
2019 | Year | 01 | Month | 01 | Day |
2023 | Year | 06 | Month | 30 | Day |
2023 | Year | 06 | Month | 30 | Day |
2023 | Year | 07 | Month | 15 | Day |
2024 | Year | 01 | Month | 15 | Day |
This is an observational study. Of the patients who visited the division of nephrology of the Tsukinomori clinic, all patients fulfilling the selection criteria are targeted.
2018 | Year | 12 | Month | 30 | Day |
2024 | Year | 02 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040349